Figures & data
Figure 1. Among 23,367, 511 health plan enrollees, 2,359 patients met selection criteria for this analysis.
Figure 2. The record for each patient was examined over a 6-month baseline period and a follow-up period of up to 12 months after the index claim for etanercept.
Table 1. Number and percent of patients included in each analysis, by initial diagnosis and starting dosage*.
Table 2. Patient demographics and clinical characteristics.
Figure 3. The weighted average actual dose was between 98% and 104% of the expected dose, depending on whether usage of patients with both psoriasis and psoriatic arthritis was compared with the expected dose for psoriasis (lower bound) or for psoriatic arthritis (upper bound).
Table 3. Etanercept usage patterns: actual dose as a percentage of expected dose.